Clinical trials: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Respiratory Tract Infection
A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
This Phase 2b study will evaluate the safety, tolerability, and immunogenicity of an RSV vaccine in pregnant participants who receive either one of 2 dose levels of the vaccine, formulated with or without aluminum hydroxide, or…
- Trial name
- NCT04032093
- Testing
- RSV vaccine
- Where
- 159 sites in United States, Argentina and 3 more
- Volunteers
- 1,153 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus Infections
A Study of AK0529 in Chinese Infants Hospitalized With RSV
This is a randomized, double-blind, placebo-controlled, multicenter, phase III study to be conducted in infants hospitalized with RSV infection in China.
- Trial name
- AIRFLO (NCT04231968)
- Testing
- AK0529
- Where
- 28 sites in China
- Volunteers
- 311 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Respiratory Syncytial Virus Infections
Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)
This study is to evaluate the antiviral effect of GS-5806 in healthy adults infected with a strain of Respiratory Syncytial Virus.
- Trial name
- Challenge (NCT01756482)
- Testing
- GS-5806
- Where
- United Kingdom
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Respiratory Syncytial Virus Vaccination
First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
- Trial name
- NCT06194318
- Testing
- Candidate vaccine, SCB-1019, candidate vaccine, SCB-1019T, AREXVY
- Where
- 2 sites in Australia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
RSV Infection
A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in healthy subjects infected with RSV-A Memphis 37b.
- Trial name
- NCT03691623
- Testing
- EDP-938 Dose 1, EDP-938 Dose 2, EDP-938 Dose 3
- Where
- United Kingdom
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Respiratory Syncytial Virus Infections
The Epidemiology , Health and Economic Burden of RSV Amongst Hospitalized Children Under 5 Years of Age in Jordan
RSV has a global healthcare burden and vaccine in the main preventive measure. There are no recent published studies that have evaluated the burden of RSV infections in the Middle East in term of incidence at a national level…
- Trial name
- RSV-JO (NCT05562817)
- Where
- Jordan
- Volunteers
- 1,200 people
- Sponsor
- MENA Center for Research & Development and Internship
Respiratory Syncytial Viral Infections
Phase I Study for SynGEM, an Intranasal Respiratory Syncytial Virus (RSV) Prefusion F Subunit Candidate Vaccine
The study is a double-blind (within dose level), placebo-controlled Phase I study to assess the safety, reactogenicity and tolerability of two intranasal dose levels of SynGEM®: a low dose level (140 μg F-protein/2mg BLPs) and a…
- Trial name
- SynGEM (NCT02958540)
- Testing
- SynGEM
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mucosis BV
RSV Infection
Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine
The purpose of this research study is to evaluate whether the investigational, live attenuated, intranasally delivered vaccine MV-012-968 ('study vaccine') may have prophylactic efficacy against symptomatic RSV infection when…
- Trial name
- NCT04690335
- Testing
- MV-012-968
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Meissa Vaccines, Inc.
Infections, Respiratory Syncytial Virus
Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression
This study is to determine danirixin (GSK1325756) concentrations required to inhibit neutrophil activation in blood obtained from Respiratory Syncytial Virus (RSV)-infected children <2 years and healthy adults.
- Trial name
- NCT02201303
- Testing
- Danirixin, CXCL1
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
RSV Infection
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects
A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Cyclosporine and Prednisone on the Pharmacokinetics and Safety of EDP-938 in Healthy Adult Subjects
- Trial name
- NCT03750383
- Testing
- EDP-938, Cyclosporine, Prednisone
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65…
- Trial name
- NCT05559476
- Testing
- RSVPreF3 OA investigational vaccine, FLU HD vaccine
- Where
- 46 sites in United States
- Volunteers
- 1,029 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Infections, Acute, Respiratory Syncytial Virus
RSV Challenge in Healthy Adults
The purpose of this study is to measure the immune response (how the body fights infection) to an experimental preparation of live Respiratory Syncytial Virus (RSV).
- Trial name
- NCT00100373
- Testing
- RSV challenge material
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human, COVID-19
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections
The goal of this decentralized, observational study is to enroll and observe adults in the contingent United States during the 2023-2024 flu season.
- Conditions
- Influenza, Human, COVID-19, Influenza A, Influenza B
- Trial name
- WAVE (NCT06207929)
- Where
- United States
- Volunteers
- 18,157 people, healthy volunteers welcome
- Sponsor
- Evidation Health
RSV Acute Respiratory Infection
Disease Burden of RSV
Respiratory diseases are one of the leading causes of morbidity and mortality among young children, and respiratory syncytial virus (RSV) is the most common pathogen causing these respiratory diseases in this age group.
- Trial name
- RSV ComNet III (NCT05506670)
- Testing
- Diagnostic test and phone call, Diagnostic test
- Where
- 5 sites in France
- Volunteers
- 84 people
- Sponsor
- Hospices Civils de Lyon
Respiratory Syncytial Virus Infection
Prevention of RSV Infections in Bone Marrow Transplant Recipients
Respiratory Syncytial Virus (RSV) infections are very common and widespread. By age 5, virtually everyone has been infected and developed antibodies against some strain of the virus.
- Trial name
- NCT00001903
- Testing
- RSV Polyclonal Immunoglobulin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infections
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults
This is a randomized, double-blind, placebo-controlled, single ascending dose escalation and two-dose study in healthy adults. This study will be conducted in healthy men and women ≥18 years old to assess the safety, tolerability…
- Trial name
- STR-V003 (NCT06344975)
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Starna Therapeutics
Healthy
An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults
The purpose of this study is to assess a trend for the prophylactic efficacy of a single dose of 1*10^11 virus particles (vp) of adenovirus serotype 26 respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) administered…
- Trial name
- NCT03334695
- Testing
- Ad26.RSV.preF
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Aspergillosis, Candidemia
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
OBSERVATIONAL STUDY OF INFECTIOUS COMPLICATIONS IN CANCER PATIENTS
- Conditions
- Aspergillosis, Candidemia, C. Difficile
- Trial name
- NCT01622595
- Where
- United States
- Sponsor
- University of Arkansas
Streptococcus Pneumoniae Infection, Respiratory Syncytial Virus Infections
Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus
This household-based prospective cohort study aims to stablish the household transmission of Respiratory syncytial virus and S. pneumoniae especially in the elderly and infants/children as well as inter-relationship between S.
- Trial name
- NCT05017519
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Mackay Memorial Hospital
Infective Organism Causing Respiratory Diseaseand Meningitis
A Prospective Household Observational Cohort Study of Influenza, Respiratory Syncytial Virus and Other Respiratory Pathogens Community Burden and Transmission Dynamics in South Africa
Title: A Prospective Household observational cohort study of Influenza, Respiratory Syncytial virus and other respiratory pathogens community burden and Transmission dynamics in South Africa (The PHIRST Study) This study will…
- Trial name
- PHIRST-SA (NCT02519803)
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- National Institute for Communicable Diseases, South Africa